Brokers Issue Forecasts for Annexon FY2025 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Annexon in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($0.99) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Several other equities research analysts have also recently issued reports on ANNX. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.80.

Annexon Stock Down 0.5 %

NASDAQ ANNX opened at $4.15 on Wednesday. The business’s fifty day simple moving average is $5.03 and its 200-day simple moving average is $5.91. The firm has a market cap of $442.35 million, a PE ratio of -3.95 and a beta of 1.11. Annexon has a 52 week low of $3.86 and a 52 week high of $8.40.

Institutional Trading of Annexon

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in shares of Annexon by 16.0% during the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after buying an additional 235,810 shares during the period. Geode Capital Management LLC lifted its stake in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after acquiring an additional 331,269 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Annexon by 16.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock valued at $29,346,000 after acquiring an additional 832,617 shares during the period. Point72 Europe London LLP acquired a new position in Annexon in the 2nd quarter valued at about $1,150,000. Finally, Barclays PLC increased its stake in Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after purchasing an additional 120,789 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.